Health AI Central
Peer-Reviewed Publication
Expert Rev Vaccines2026;25(1):2721744.December 1, 2026Journal Article

United States healthcare providers' views on pediatric meningococcal disease and vaccination.

Oscar Herrera-Restrepo1, Vasudha Gupta2, Sophie Jacobovitz2, Tosin Olaiya1, Elise Kuylen3, Karam Dahyaleh1, Kristin K Johnson1, Thatiana Pinto3, Sofia B Pinto4, Jana Shaw5
1GSK, Philadelphia, PA, USA.
2IQVIA, Durham, NC, USA.
3GSK, Wavre, Belgium.
4GSK, Rio de Janeiro, Brazil.
5SUNY Upstate University Hospital, Syracuse, NY, USA.
PubMed DOI

Abstract

BACKGROUND: Although meningococcal serogroup B (MenB) causes most invasive meningococcal disease (IMD) cases in United States (US) infants, MenB vaccination is not currently approved for this age group. This study sought to better understand US healthcare providers' (HCPs') views regarding IMD and a potential MenB vaccine for children ≤18 months old. RESEARCH DESIGN AND METHODS: An online survey…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.